• Embed Doc
  • Copy Link
  • Readcast
  • Collections
  • CommentGo Back
Download
 
PETER BRENDERS
President and CEOBIOTECanada
Peter Brenders joined BIOTECanada as President & CEO in February 2005. Previously, he workedin health and corporate affairs in senior management roles at Genzyme Canada and Schering-Plough Canada. Mr. Brenders has also worked in the Ontario Ministry of Health and in the healthconsulting practice at KPMG.Mr. Brenders is currently a member of the Advisory Board for the National Research Council’s (NRC)Institute for Marine Biosciences and the NRC’s Institute for Nutrisciences and Health, a member of the Department of Foreign Affairs and International Trade’s Life Sciences Advisory Board and theIndustry Advisor for the Atlantic Canada Opportunity Agency’s Atlantic Innovation Fund Committeesfor Aquaculture and Biotechnology Sector and Health and Medical Sector. He is a member of the Advisory Council for Algonquin College’s biotechnology program, and has served as a member of thePrivy Council Office’s Reference Group on Regulating, as a Board member and Treasurer of theRegistered Nurses Association of Ontario Foundation, and has served as the Chair of its TorontoChapter of the Canadian College of Health Services Executives.Mr. Brenders regularly offers industry presentations at domestic and international events and conducts regular lectures tograduate classes at McMaster University. He received his MBAin Health Services Management from McMaster University. Prior to his brief work in basic research at the Robarts Research Institute, he received his honours BSc in Pharmacology and Toxicologyfrom the University of Western Ontario.
MICHAELBROGRAN
PresidentIMS Brogan - AUnit of IMS
Michael Brogan, President of IMS Brogan, is responsible for the Canadian business unit of IMSHealth. He has lead the company’s Canada operations since February 2011.Michael joined the organization in 2010 as Vice-President, Sales and Marketing following the merger of IMS’s Canadian business with Brogan, Inc., a market research and consulting firm servingCanada’s healthcare market.Prior to IMS, Michael held roles of increasing responsibility at Brogan, Inc., leading the company’ssales, marketing, product management and consulting functions. As lead business architect, he alsodrove the design and development of the company’s innovative offerings portfolio servinggovernment, payers and pharmaceutical companies. He joined the company in 1998. Michael holdsa bachelor’s degree in journalism from Carleton University.
DEBORAH BROWN
Managing Director/PresidentEMD Canada Inc.
Deborah Brown is the Canadian President of EMD Canada, an affiliate of Merck Serono and Merck KGaA. Deborah completedundergraduate and graduate studies in science and business from the University of Guelph and the Richard Ivey School of Business at the University of Western Ontario. Her pharmaceutical career has included positions in regulatory affairs, biometrics,sales management, research, marketing, and general management. Deborah has led the launch of several leading biologicproducts in both the US and Canada.
2011 Faculty
 
In her current capacity as President of EMD Serono Canada, she oversees one of Canada’s mostsuccessful commercial biotechnology companies, offering or developing niche prescription drugs inthe areas of neurodegenerative disease, endocrinology, rheumatology, oncology and fertility. Theyhave been named a GTATop Employer in both 2009 and 2010.Deborah serves on the Executive Committee and Board of Rx&D, chairs the Industry PracticesCommittee, and is a past board and executive committee member of BIOTECanada.In addition to her corporate responsibilities, Deborah is involved in her community and severalcharitable organization. She is a founding member of Women Against MS (WAMS) which is a specialfundraising group of the MS Society, the Toronto Humane Society, McMaster Children’s Hospital, andthe three organizations that EMD Serono actively supports—the Mississauga Food Bank, HaltonWomen’s Place and the Halton Learning Foundation.
JILLDONAHUE, Hba, MadEd
Speaker, Writer, Behaviour Change Consultant to PharmaExcellerate
Jill Donahue Hba, MAded, author of PERSUASION Rx: How to Influence Ethically (now CCPE’smost popular course), is fascinated with behaviour change in healthcare. Through her energizing keynotes, workshops, coaching and consulting, she brings the ah-ha’s to how toinfluence others—health care professionals, patients, your audience, your team, even your spouse. From ‘uninterested’to ‘on board’she has tips for every step of the way.While Jill brings a strong academic background to her work, what marvels her pharma clients isher talent to translate the theory of behaviour change to practical application to help pharmaprofessionals from all departments and health care professionals influence more effectively.Says one client:“Jill is the guru of behaviour change—the “go to” company for those in healthcare to learn howto influence behaviour change and improve patient outcomes.”Founder and chair of Bricks and Books, the “do good, feel good” leadership event of the year for pharmaceutical industryprofessionals, Jill and her volunteer team are creating good news headlines for the pharma community in Canada. Theyare aiming to build two schools in Nepal through this popular conference built by and for pharma. Mark your calendars for Oct 5, right here at Hilton Garden Inn. Early bird registration opens today March 30 at
www.bricksandbooksevent.com
.For insight on the ideas and solutions she offers, visit
www.excellerate.ca
. Look for the “Loot Bag" where you can downloada FREE self-reflection exercise and article “Are you an influencer? How to Influence in Pharma.”
PAT FORSYTHE
Neuroscience Business Unit Director Allergan Inc.
Pat Forsythe,Neuroscience Business Director at Allergan Canada has over 20 years of sales andmarketing experience in the Canadian Pharmaceutical industry in a range of therapeutic areas fromSpecialty Biotech to traditional Primary Care. Prior to Allergan, Pat worked with Altana Pharma inthe Gastroenterology and Respiratory categories and with Roche in Hepatitis, Cardiovasculars and Antimicrobials. He started his career with the Upjohn Company of Canada.Pat's sales and marketing career has been characterized by a strong focus on a customer centricapproach balanced with the reality of the business needs. His work has been characterized byconstant innovation and an entrepreneurial approach to meeting customer needs.Pat has been involved in 12 product launches and is currently working with his team to prepare for additional launches in 2011 through 2014..
 
MORRIS GOODMAN
Chairman of the BoardPharmascience inc.
Born in Montreal on September 14, 1931, Morris Goodman is Chairman of the Board of PharmascienceInc., a company that he co-founded in June 1983. Morris Goodman graduated from the Faculty of Pharmacy at the University of Montreal in 1953 at the age of twenty-one, the youngest graduate of thatfaculty at that time, and obtained the University of Montreal's Prize for Success.Upon obtaining his degree, Morris Goodman chose to embark on the industry side of pharmacy, andquickly obtained distribution rights from several international pharmaceutical companies in order to bringtheir products to the Canadian marketplace. Specializing in the therapeutic areas of dermatology andtuberculosis, Morris Goodman marketed and sold these products in Canada under the company nameof Winley-Morris Co. Ltd.In 1971, Morris Goodman approached a California-based company named International Chemical &Nuclear Corporation (which subsequently became ICN), to become their Canadian distributor of L-Dopa.Impressed with his innovative approach, ICN negotiated to purchase Winley-Morris and established Morris Goodman as CEO of ICNCanada. After successfully running ICN for over ten years, Morris Goodman left ICN in 1983 to begin a brand new innovative genericenterprise, Pharmascience Inc. As Co-Founder & Chairman of the Board of Pharmascience Inc., Morris Goodman has been at the forefront of the explosive growthand development of Pharmascience, leading it to its current standing as one of the top three generic pharmaceutical companies inCanada. As one of Canada’s leading entrepreneurs, Morris Goodman is committed to “Creating The Difference” for the healthcare industry inCanada and worldwide.
DOUG GRANT
Senior Vice President and Head, Corporate AffairsBayer Inc.
Doug Grant is the Senior Vice President and Head of Corporate Affairs at Bayer Inc. In his role, Dougis responsible for providing management, leadership and strategic direction for Communications,Trade Relations, Contracts, Pricing, Reimbursement, Federal and Provincial Government Affairs, aswell as overseeing the Hematology business unit.Doug began his career at Bayer in 2001 and has held numerous positions within the organization.Prior to joining Bayer, Doug held various senior management roles at Bristol-Myers Squibb Canada,Pfizer Canada and Marion Merrell Dow. After three years of being the Vice-Chair of Canada’s Research-Based Pharmaceutical Companies'(Rx&D) Provincial Affairs Committee, Doug is moving to a new role with the Strategic Advisory Groupof Rx&D. Rx&D is the national association representing more than 22,000 employees working for over 50 pharmaceuticals companies across Canada. In addition, Doug is returning for another termas a MEDEC (Medical Device Industry in Canada) Board Member. MEDEC is the nationalassociation representing more than 35,000 employees working for over 1,500 corporate facilities.Doug is a graduate of York University and is an active member of several industry associations. He is also a past member of several industry boards including the Institute of Health Economics and the Council for Continuing Pharmaceutical Education.
ROBIN HUNTER
Vice President, Critical CareLEO Pharma
Founded more than 100 years ago, LEO Pharma is a research-based, specialty pharmaceutical company committed to thediscovery and development of novel drugs. LEO Pharma is wholly owned by the LEO Foundation, an independent and privateinstitution headquartered in Denmark.
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...